Aurinia Pharmaceuticals
AUPH
214 hedge funds and large institutions have $504M invested in Aurinia Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 67 increasing their positions, 60 reducing their positions, and 20 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
86% more call options, than puts
Call options by funds: $14.4M | Put options by funds: $7.71M
85% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 20
12% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 60
7% more funds holding
Funds holding: 200 → 214 (+14)
4.79% more ownership
Funds ownership: 40.86% → 45.65% (+4.8%)
4% less capital invested
Capital invested by funds: $525M → $504M (-$21.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$13M |
| 2 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$6.1M |
| 3 |
Morgan Stanley
New York
|
+$5.85M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$5.35M |
| 5 |
Lazard Asset Management
New York
|
+$5.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$11.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.63M |
| 3 |
Citigroup
New York
|
-$4.52M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$2.83M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$2M |
AUPH Hedge Fund Activity: Q1 2025 in Review
214 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q1 2025, worth a combined $504M — down 4% from $525M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new AUPH positions and 20 closed out — a net gain of 17 holders — while 67 added to existing stakes and 60 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $13M. The largest seller was Armistice Capital, cutting an estimated $11.3M.
- 214 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q1 2025, up from 200 in Q4 2024.
- Funds reported $504M of Aurinia Pharmaceuticals stock for Q1 2025, down 4% quarter-over-quarter.
- 37 funds opened new Aurinia Pharmaceuticals positions in Q1 2025 and 20 closed out, a net change of +17 holders.
- The largest Aurinia Pharmaceuticals buyer in Q1 2025 was Tang Capital Management, an estimated $13M added.
- The largest Aurinia Pharmaceuticals seller in Q1 2025 was Armistice Capital, an estimated $11.3M sold.
Based on aggregated 13F filings for Q1 2025.